MedPage Today January 14, 2025
— Three largest PBMs reimbursed own pharmacies at higher rates than independent ones, report finds
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
“The FTC staff’s second interim report finds that the three major pharmacy benefit managers” — Caremark Rx, Express Scripts, and OptumRx — “hiked costs for a wide range of lifesaving drugs, including medications to treat heart disease and cancer,” said outgoing FTC Chair Lina Khan in a press release.
The costs of these specialty generic medications, which also included treatments for HIV...
Today's Sponsors
Today's Sponsor